H. Üsküdar Teke, "Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial," Lancet Oncology , vol.20, no.6, pp.781-794, 2019
Üsküdar Teke, H. 2019. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology , vol.20, no.6 , 781-794.
Üsküdar Teke, H., (2019). Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology , vol.20, no.6, 781-794.
Üsküdar Teke, HAVA. "Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial," Lancet Oncology , vol.20, no.6, 781-794, 2019
Üsküdar Teke, HAVA Ü. . "Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial." Lancet Oncology , vol.20, no.6, pp.781-794, 2019
Üsküdar Teke, H. (2019) . "Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial." Lancet Oncology , vol.20, no.6, pp.781-794.
@article{article, author={HAVA ÜSKÜDAR TEKE}, title={Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial}, journal={Lancet Oncology}, year=2019, pages={781-794} }